Systemic lupus erythematosus

A Clinician's Pearls and Myths in Rheumatology

Volumn , Issue , 2009, Pages 131-159

  Petri, Michelle ^a   Abuav, Rachel ^b   Boumpas, Dimitrios ^c   Goldblatt, Fiona ^d   Isenberg, David ^e   Anhalt, Grant J ^b   Werth, Victoria P ^f   Looney, R John ^g  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c UNIVERSITY OF CRETE   (Greece)

^d ROYAL ADELAIDE HOSPITAL   (Australia)

^e UNIVERSITY COLLEGE LONDON   (United Kingdom)

^f UNIVERSITY OF PENNSYLVANIA   (United States)

^g UNIVERSITY OF ROCHESTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84889995034     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-84800-934-9_13     Document Type: Chapter

References (152)

1. Abu-Shakra M, Zalmanson S, Neumann L, Flusser D, Sukenik S, Buskila D. Influenza virus vaccination of patients with systemic lupus erythematosus: Effects on disease activity. J Rheumatol 2000; 27(7):1681-1685
2. ACR ad hoc committee on neuropsychiatric lupus. The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndrome. Arthritis Rheum 1999; 42:599-608
3. Adler M, Chambers S, Edwards C, Neild G, Isenberg D. An assessment of renal failure in an SLE cohort with special reference to ethnicity, over a 25-year period. Rheumatology 2006; 45:1144-1147
4. Advisory Committee on Immunization Practices (ACIP). Recommendations for the Prevention of Herpes Zoster Morbidity and Mortality Weekly Report Recommendations and Reports June 6, 2008/Vol. 57/RR-5(www.cdc.gov/mmwr)
5. Aguilera P, Mascaró JM Jr., Martinez A, et al Cutaneous gamma/delta T-cell lymphoma: A histopathologic mimicker of lupus erythematosusprofundus (lupus panniculitis). J Am AcadDermatol 2007; 56: 643-647
6. Ainiala H, Loukkola J, Peltola J, Korpela M, Hietaharju A. The prevalence of neuropsychiatric syndromes in systemic lupus erythematosus. Neurology 2001; 57(3):496-500
7. Akkasilpa S, Goldman D, Magder LS, Petri M. Number of fi bromyalgia tender points is associated with health status in patients with systemic lupus erythematosus. J Rheumatol 2005; 32(1):48-50
8. Appel G, Contreras G, MA D, et al Mycophenolate Mofetil versus Cyclophosphamide as Lupus Nephritis Induction Treatment. J Am Soc Nephrol 2009; 20(5):1103-12
9. Aringer M, Graninger WB, Steiner G, Smolen JS. Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus: An open-label study. Arthritis Rheum 2004; 50(10): 3161-3169
10. Austin H, Klippel J, Balow J, et al Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. NEJM 1986; 314:614-619
11. Baca V, Lavalle C, Garcia R, et al Favorable response to intravenous methylprednisolone and cyclophosphamide in children with severe neuropsychiatric lupus. J Rheumatol 1999; 26:432-439
12. Barr S, Zonana-Nacach A, Magder L, Petri M. Patterns of disease activity in systemic lupus erythematosus. Arthritis Rheum 1999; 42: 2682-2688
13. Bertsias G, Ioannidis JP, Boletis J, et al Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics. EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics. Ann Rheum Dis 2008; 67(2):195-205
14. Bijl M, Kallenberg CG. Ultraviolet light and cutaneous lupus. Lupus 2006; 15(11):724-727
15. Boddaert J, Huong D, Zahir A, Wechsler B, Godeau P, Piette J. Lateonset systemic lupus erythematosus: A personal series of 47 patients and pooled analysis of 714 cases in the literature. Medicine 2004; 83:348-359
16. Bombardier C, Gladman DD, Urowitz M, Caron D, Chang CH, the Committee on Prognosis Studies in SLE. Derivation of the SLEDAI: A disease activity index for lupus patients. Arthritis Rheum 1992; 35:630-640
17. Boumpas D, Yamada H, Patronas N, Scott D, Klippel J, Balow J. Pulse cyclophosphamide for severe neuropsychiatric lupus. Q J Med 1991; 81:975-984
18. Boumpas DT, Sidiropoulos P, Bertsias G. Optimum therapeutic approaches for lupus nephritis: what therapy and for whom? Nat Clin Pract Rheumatol 2005; 1(1):22-30
19. Brooks SM, Werk EE, Ackerman SJ, et al Adverse effects of phenobarbital on corticosteroid metabolism in patients with bronchial asthma. N Engl J Med 1972; 286:1125-1128
20. Bruce I, Gladmann D, Urowitz M. Factors associated with refractory renal disease in patients with systemic lupus erythematosus: The role of patient non-adherence. Arthritis Care Res 2000; 13:406-408
21. Buyon J, Petri MA, Kim MY, et al The effect of combined estrogen and progesterone hormone replacement therapy on disease activity in systemic lupus erythematosus: A randomized trial. Ann Intern Med 2005; 142:953-962
22. Callen JP. Cutaneous lupus erythematosus: A personal approach to management. Australas J Dermatol 2006; 47(1):13-27
23. Calvo-Alen J, Alarcon GS, Burgard SL, et al Systemic lupus erythematosus: Predictors of its occurrence among a cohort of patients with early undifferentiated connective tissue disease: Multivariate analyses and identification of risk factors. J Rheumatol 1996; 23:469-475
24. Carrie F, Roblot P, Bouquet S, et al: Rifampin-induced nonresponsiveness of giant cell arteritis to prednisone treatment. Arch Intern Med 1994; 154:1521-1524
25. Cervera R, Khamashta M, Font J, et al Systemic lupus erythematosus: Clinical and immunologic patterns of disease expression in a cohort of 1,000 patients. The European Working Party on Systemic Lupus Erythematosus. Medicine 1993; 72:113-124
26. Chambers S, Charman S, Rahman A, Isenberg D. Development of additional autoimmune diseases in a multiethnic cohort of patients with systemic lupus erythematosus with reference to damage and mortality. Ann Rheum Dis 2007; 66:1173-1177
27. Chan MT. Owen P. Dunphy J, et al Associations of erosive arthritis with anti-cyclic citrullinated peptide antibodies and MHC Class II alleles in systemic lupus erythematosus. J Rheumatol 2008; 35(1): 77-83
28. Chan TM, Li FK, Tang CS, et al Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong- Guangzhou Nephrology Study Group. N Engl J Med 2000; 343 (16):1156-1162
29. Christopher-Stine L, Siedner M, Lin H, Haas M, Parekh H, Petri M, et al Renal biopsy in lupus patients with low levels of proteinuria. J Rheumatol 2007; 34: 332-335
30. Chrysostomou A, Becker G. Spironolactone in addition to ACE inhibition to reduce proteinuria in patients with chronic renal disease. N Engl J Med 2001; 345(12):925-926
31. Contreras G, Pardo V, Leclercq B, Lenz O, Tozman E, O'Nan P, et al Sequential therapies for proliferative lupus nephritis. N Engl J Med 2004; 350(10):971-980
32. Costallat L, Coimbra A. Systemic lupus erythematosus: Clinical and laboratory aspects related to age at disease onset. Clin Exp Rheumatol 1994; 12:603-607
33. Cusack C, Danby C, Fallon JC, et al Photo protective behaviour and sunscreen use: Impact on vitamin D levels in cutaneous lupus erythematosus. Photodermatol Photoimmunol Photomed 2008; 24: 260-267
34. Damian-Abrego G, Cabiedes J, Cabral A. Anti-citrullinated peptide antibodies in lupus patients with or without deforming arthropathy. Lupus 2008; 17:300-304
35. Danowski A, Magder L, Petri M. Flares in lupus: Outcome Assessment Trial (FLOAT), a comparison between oral methylprednisolone and intramuscular triamcinolone. J Rheumatol 2006; 33(1):57-60
36. Domenech I, Aydintug O, Cervera R, et al Systemic lupus erythematosus in 50 year olds. Postgrad med J 1992; 68:440-444
37. Elkayam O, Paran D, Caspi D, et al Immunogenicity and safety of pneumococcal vaccination in patients with rheumatoid arthritis or systemic lupus erythematosus. Clin Infect Dis 2002; 34:147-153
38. Elkayam O, Paran D, Burke M, et al Pneumococcal vaccination of patients with systemic lupus erythematosus: Effects on generation of autoantibodies. Autoimmunity 2005; 38:493-496
39. Erkan D, Harrison MJ, Levy R, Peterson M, Petri M, Sammaritano L, et al Aspirin for primary thrombosis prevention in the antiphospholipid syndrome: A randomized, double-blind, placebo-controlled trial in asymptomatic antiphospholipid antibody-positive individuals. Arthritis Rheum 2007; 56(7):2382-2391
40. Esdaile JM, Abrahamowicz M, Grodzicky T, Li Y, Panaritis C, du Berger R, et al Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum 2001; 44(10):2331-2337
41. Faurschou M, Starklint H, Halberg P, Jacobsen S. Prognostic factors in lupus nephritis: Diagnostic and therapeutic delay increases the risk of terminal renal failure. J Rheumatol 2006; 33:1563-1569
42. Feldman R, Salmon D, Saurat JH. The association of the two antimalarialschloroquine and quinacrine for treatment-resistantchronic and subacutecutaneous lupus erythematosus. Dermatology 1994;186:425-427
43. Fernandez M, Calvo-Alen J, Bertoli A, et al Systemic lupus erythematosus in a multiethnic US cohort (LUMINA L II): Relationship between vascular events and the use of hormone replacement therapy in postmenopausal women. J Clin Rheumatol 2007; 13:261-265
44. Fernandez-Nebro A, Palacios-Munoz R, Gordillo J, Abarca-Costalago M, De Haro-Liger M, Rodriguez-Andreu J, et al Chronic or recur rent headache in patients with systemic lupus erythematosus: A case control study. Lupus 1999; 8(2):151-156
45. Fessler B. Infectious diseases in systemic lupus erythematosus:risk factors, management and prophylaxis. Best Pract Res Clin Rheumatol 2002; 16:281-291
46. Fessler BJ, Alarcon GS, McGwin G, Jr., Roseman J, Bastian HM, Friedman AW, et al Systemic lupus erythematosus in three ethnic groups: XVI. Association of hydroxychloroquine use with reduced risk of damage accrual. Arthritis Rheum 2005; 52(5):1473-1480
47. Font J, Pallares L, Cervera R, et al Systemic lupus erythematosus in the elderly: Clinical and immunological charracteristics. Ann Rheum Dis 1991; 50:702-705
48. Foote R, Kimbrough S, Stevens J. Lupus myositis. Muscle Nerve 1982; 5:65-68
49. Formiga F, Moga I, Pac M, Mitjavila F, Rivera A, Pujol R. Mild presentation of systemic lupus erythematosus in elderly patients assessed by SLEDAI. Lupus 1999; 8:462-465
50. Fusconi M, Vannini A, Dall'aglio AC, Pappas G, Bianchi FB, Zauli D. Etanercept and infl iximab induce the same serological autoimmune modifications in patients with rheumatoid arthritis. Rheumatol Int 2007; 28(1):47-49
51. Ganczarczyk L, Urowitz MB, Gladman DD. Latent lupus. J Rheumatol 1989; 16:475-478
52. Geraminejad P, Stone MS, Sontheimer RD. Antimalarial lichenoid tissue reactions in patients with pre-existing lupus erythematosus. Lupus 2004; 13:473-477
53. Gilland WR, Tsokos GC. Prophylactic use of antibiotics and immunisations in patients with SLE. Ann Rheum Dis 2002 Mar; 61(3):191-192
54. Gilliam JN, Cheatum DE, Hurd ER, Stastny P Ziff M. Immuno globulin in clinically uninvolved skin in systemic lupus erythematosus: Association with renal disease. J clin invest 1974; 53(5): 1434-1440
55. Ginsburg KS, Liang MH, Newcomer L, et al Anticardiolipin antibodies and the risk for ischemic stroke and venous thrombosis. Ann Intern Med 1992; 117:997-1002
56. Ginzler EM, Dooley MA, Aranow C, Kim MY, Buyon J, Merrill JT, et al Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med 2005; 353(21):2219-2228
57. Gladman D, Hussain F, Ibanez D, Urowitz M. The nature and outcome of infection in systemic lupus erythematosus. Lupus 2002; 11:234-239
58. Glas-Vos Jd, Krediet R, Weening J, Arisz L. Treatment of proliferative lupus nephritis with methylprednisolone pulse therapy and oral azathioprine. Neth J Med 1995; 46:4-14
59. Godeau B, Coutant-Perronne V, Le Thi Huong D, et al Pneumocystis carinii pneumonia in the course of connective tissue disease: Report of 34 cases. J Rheumatol 1994; 21(2):246-251
60. Gorbache AV, Gasparian AV, Gurova KV, et al Quinacrine inhibits the epidermal dendritic cell migration initiating T cell-mediated skin infl ammation. Eur J Immunol 2007; 37:2257-2267
61. Graninger, Smolen JS. Incomplete lupus erythematosus: Results of a multicentre study under the supervision of the EULAR Standing Committee on International Clinical Studies Including Therapeutic Trials (ESCISIT). Rheumatology (Oxford) 2001; 40:89-94
62. Grootscholten C, Ligtenberg G, Hagen E, et al Azathioprine/ methylprednisolone versus cyclophosphamide in proliferative lupus nephritis. A randomized controlled trial. Kidney Int 2006; 70:732-742
63. Hesselink D, Aarden L, Swaak A. Profi les of the acute-phase reactants C-reactive protein and ferritin related to the disease course of patients with systemic lupus erythematosus. Scand J Rheumatol 2003; 32:151-155
64. Ho C, Mok C, Lau C, Wong R. Late onset systemic lupus erythematosus in southern Chinese. Ann Rheum Dis 1998; 57:437-444
65. Ho A, Magder L, Barr S, Petri M. Decreases in anti-double stranded DNA levels are associated with concurrent fl ares in patients with systemic lupus erythematosus. Arthritis Rheum 2001a; 44: 2342-2349
66. Ho A, Magder LS, Barr SG, Petri MA. A decrease in complement is associated with increased renal and hematologic flares in patients with systemic lupus erythematosus. Arthritis Rheum 2001b; 44: 2350-2357
67. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [letter]. Arthritis Rheum 1997; 40:1725
68. Huong DL, Papo T, Beaufuls H, Wechsler B. Renal involvement in systemic lupus erythematosus: A study of 180 patients from a single center. Medicine (Baltimore) 1999; 78:148
69. Iaboni A, Ibanez D, Gladman DD, Urowitz MB, Moldofsky H. Fatigue in systemic lupus erythematosus: Contributions of disordered sleep, sleepiness, and depression. J Rheumatol 2006; 33(12):2453-2457
70. Iliopoulos A, Tsokos G. Immunopathogenesis and spectrum of infections in systemic lupus erythematosus. Semin Arthritis Rheum 1996; 25:318-336
71. Ioannidis JP, Boki KA, Katsorida ME, et al Remission, relapse, and reremission of proliferative lupus nephritis treated with cyclophosphamide. Kidney Int 2000; 57(1):258-264
72. Irving KS, Sen D, Tahir H, et al A comparison of autoimmune liver disease in juvenile and adult populations with systemic lupus erythematosus- a retrospective review of cases. Rheumatology (Oxford) 2007; 46(7):1171-1173
73. Isenberg D, Horsfall A. Systemic lupus erythematosus-adult onset. In: Maddison P, Isenberg D, Woo P, Glass D (eds) Oxford textbook of rheumatology. Oxford, Oxford University Press, 1998, pp. 1145-1180
74. Jewell ML, McCauliffe DP. Patients with cutaneous lupus erythematosus who smoke are less responsive to antimalarial treatment. J Am AcadDermatol 2000; 42:983-987
75. Jonsdottir T, Forslid J, van Vollenhoven A, Harju A, Brannemark S, Klareskog L, et al Treatment with tumour necrosis factor alpha antagonists in patients with rheumatoid arthritis induces anticardiolipin antibodies. Ann Rheum Dis 2004; 63(9):1075-1078
76. Jorizzo JL, Salisbury PL, Rogers RS 3rd, Goldsmith SM, Shar GG, Callen JP, Wise CM, Semble EL White WL. Oral lesions in systemic lupus erythematosus. Do ulcerative lesions represent a necrotizing vasculitis?. J Am Acad Dermatolo 1992; 27(3):389-394
77. Kalia S, Dutz JP. New concepts in antimalarial use and mode of action in dermatology. DermatolTher 2007; 20:160-174
78. Karpatkin S. Autoimmune thrombocytopaenic purpura. Semin Haematol 1985; 22:260-288
79. Kasitanon N, Fine DM, Haas M, Magder LS, Petri M. Hydroxychloroquine use predicts complete renal remission within 12 months among patients treated with mycophenolate mofetil therapy for membranous lupus nephritis. Lupus 2006; 15(6):366-370
80. Klippel JH, Karsh J, Stahl NI, et al A controlled study of pneumococcal polysaccharide vaccine in systemic lupus erythematosus. Arthritis Rheum 1979; 22:1321-1325
81. Koneru S, Shishov M, Ware A, Farhey Y, Mongey AB, Graham TB, et al Effectively measuring adherence to medications for systemic lupus erythematosus in a clinical setting. Arthritis Rheum 2007; 57(6):1000-1006
82. Kroshinsky D, Stone JH, Bloch D, Stone JR. A 47-year-old woman with a nodular rash and numbness and pain in the legs. New England Journal of Medicine 2009; 360(7):711-20
83. Lee SS, Singh S, Magder LS, Petri M. Predictors of high sensitivity C-reactive protein levels in patients with systemic lupus erythematosus. Lupus 2008; 17:114-23
84. Lin A. Chapter 36: Topical calcineurin inhibitors. In: Wolverton SE (ed) Comprehensive dermatologic drug therapy (2nd edn). Philadelphia, PA, Saunders Elsevier, 2007, pp. 671-689
85. MacGowan J, Ellis S, Griffiths M, Isenberg D. Retrospective analysis of outcome in a cohort of patients with lupus nephritis treated between 1977 and 1999. Rheumatology 2002; 41:981-987
86. Mackay IR et al Lupoid hepatitis and the hepatic lesions of systemic lupus erythematosus Lancet 1959 1: 65
87. Manoussakis M, Georgopoulou C, Zintzaras E, et al Sjogren's syndrome associated with systemic lupus erythematosus: Clinical and laboratory profi les and comparison with primary Sjogren's syndrome. Arthritis Rheum 2004; 50:882-891
88. Manzi S, Meilahn E, Rairie J, et al Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: Comparison with the Framingham Study. Am J Epidemiol 1997; 145:408-415
89. Marmor MF, Carr RE, Easterbrook M, et al Recommendations on screening for chloroquine and hydroxychloroquine retinopathy. A report by the American Academy of Ophthalmology. Ophthalmology 2002; 109:1377-1382
90. McDonagh J, Isenberg D. Development of additional autoimmune disease in a population of patients with systemic lupus erythematosus. Ann Rheum Dis 2000; 59:230-232
91. Middleton GD, McFarlin JE, Lipsky PE. The prevalence and clinical impact of fi bromyalgia in systemic lupus erythematosus. Arthritis Rheum 1994; 37(8):1181-1188
92. Miot HA, Bartoli MLD, Haddad GR. Association between discoid lupus erythematosus and cigarette smoking. Dermatology 2005; 211:118-122
93. Modi GM, Maender JL, Coleman N, et al. Tineacorporis masquerading as subacutecutaneous lupus erythematosus. Dermatol Online J 2008; 15; 14(4):8
94. Moghadam-Kia S, Chilek K, Gaines E, et al. Cross-sectional analysis of a collaborative web-based database for lupus erythematosus associated skin lesions: 114 prospectively enrolled patients. Arch Dermatol 2009; 145(3):255-60
95. Mok C. Prognostic factors in lupus nephritis. Lupus 2005; 14:39-44
96. Neuwelt C, Lacks S, Kaye B, Ellman J, Borenstein D. Role of intravenous cyclophosphamide in the treatment of severe neuropsychiatric systemic lupus erythematosus. Am J Med 1995; 98:32-41
97. Ng K, Manson J, Rahman A, Isenberg D. Association of antinucleosome antibodies with disease fl are in serologically active clinically quiescent patients with systemic lupus erythematosus. Arthritis Care Res 2006; 55:900-904
98. Niiyama S, Katsuoka K, Happle R Hoffmann R. Multiple eruptive dermatofi bromas: A review of the literature. Acta Derm Venereol 2002; 82(4):241-244
99. Nimmagadda SR, Spahn JD, Leung DY, Szefl er SJ. Steroid-resistant asthma: Evaluation and management. [Review] [76 refs] [Journal Article. Research Support, Non-U.S. Gov't. Review] Ann Allergy Asthma Immunol 1996 Nov; 77(5):345-355; quiz 355-356
100. Noel V, Lortholary O, Casassus P, et al Risk factors and prognostic influence of infection in a single cohort of 87 adults with systemic lupus erythematosus. Ann Rheum Dis 2001; 60:1141-1144
101. Nossent H, Koldingsnes W. Long-term efficacy of azathioprine treatment for proliferative lupus nephritis. Rheumatology 2000; 39:969-974
102. Omdal R, Mellgren SI, Koldingsnes W, Jacobsen EA, Husby G. Fatigue in patients with systemic lupus erythematosus: Lack of associations to serum cytokines, antiphospholipid antibodies, or other disease characteristics. J Rheumatol 2002; 29(3):482-486
103. O'Neill S, Isenberg D. Immunizing patients with systemic lupus erythematosus: A review of effectiveness and safety. Lupus 2006; 15: 778-783
104. Para MF, Finkelstein D, Becker S, et al Reduced toxicity with gradual initiation of trimethoprim-sulfamethoxazole as primary prophylaxis for Pneumocystis carinii pneumonia: AIDS Clinical Trials Group 268. JAIDS 2000; 24(4):337-343
105. Pego-Reigosa JM, Isenberg DA. Psychosis due to systemic lupus erythematosus: Characteristics and long term outcome of this rare manifestation of the disease. Rheumatology 2008; 47:1498-1502
106. Perl A, Nagy G, Gergely P, et al Apoptosis and mitochondrial dysfunction in lymphocytes of patients with systemic lupus erythematosus. Methods Mol Med 2004; 102:87-114
107. Petri M. Musculoskeletal complications of systemic lupus erythematosus in the Hopkins Lupus Cohort: an update. Arthritis Care Res 1995; 8:137-145
108. Petri M. Thrombosis and systemic lupus erythematosus: The Hopkins Lupus Cohort perspective. Scand J Rheumatol 1996; 25:191-193
109. Petri M. Infection in systemic lupus erythematosus. Rheumatic Dis Clin N Am 1998; 24:423-456
110. Petri M, Allbritton J. Antibiotic allergy in systemic lupus erythematosus: A case-control study. J Rheumatol 1992; 19(2):265-269
111. Petri M, Perez-Gutthann S, Longenecker J, Hochberg M. Morbidity of systemic lupus erythematosus: Role of race and socioeconomic status. Am J Med 1991a; 91:345-353
112. Petri M, Genovese M, Engle E, Hochberg M. Definition, incidence and clinical description of fl are in systemic lupus erythematosus: A prospective cohort study. Arthritis Rheum 1991b; 34:937-944
113. Petri M, Kim MY, Kalunian KC, et al Combined oral contraceptives in women with systemic lupus erythematosus. N Engl J Med 2005; 353:2550-2558
114. Pichler WJ. Delayed drug hypersensitivity reactions. Ann Intern Med 2003; 139(8):683-693
115. Pierangeli SS, Harris EN. In vivo models of thrombosis for the antiphospholipid syndrome. Lupus 1996; 5(5):451-455
116. Porges AJ, Beattie SL, Ritchlin C, et al Patients with systemic lupus erythematosus at risk for Pneumocystis carinii pneumonia. J Rheumatol 1992; 19(8):1191-1194
117. Provost TT, Andres G, Maddison PJ Reichlin M. Lupus band test in untreated SLE patients: Correlation of immunoglobulin deposition in the skin of the extensor forearm with clinical renal disease and serological abnormalities. J Invest Dermatol 1980; 74(6): 407-412
118. Pyne D, Isenberg D. Autoimmune thyroid diseases in systemic lupus erythematosus. Ann Rheum Dis 2002; 61:70-72
119. Ramos P, Mendez M, Ames P, Khamashta M, Hughes G. Pulse cyclophosphamide in the treatment of neuropsychiatric systemic lupus erythematosus. Clin Exp Rheumatol 1996; 14:295-299
120. Roman MJ, Shanker BA, Davis A, Lockshin MD, Sammaritano L, Simantov R, et al Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med 2003; 349(25):2399-2406
121. Ropes MW. Systemic lupus erythematosus. Cambridge, MA, Harvard University Press, 1976, p. 28
122. Roy S, Tan K. Pyrexia and normal C-reactive protein (CRP) in patients with systemic lupus erythematosus: Always consider the possibility of infection in febrile patients with systemic lupus erythematosus regardless of CRP levels. Rheumatology 2001; 40:349-350
123. Runyon BA, LaBrecque DR, Anuras S. The spectrum of liver disease in systemic lupus erythematosus. Report of 33 histologically-proved cases and review of the literature. Am J Med 1980; 69:187-194
124. Sato EI. Methotrexate therapy in systemic lupus erythematosus. Lupus 2001; 10(3):162-164
125. Scheinfeld N, Deleo VA. Photosensitivity in lupus erythematosus. Photodermatol Photoimmunol Photomed 2004; 20(5):272-279
126. Schmidt E, Brocker EB, Goebeler M. Rituximab in treatment-resistant autoimmune blistering skin disorders. Clin Rev Allergy Immunol 2008; 34(1):56-64
127. Sivaraj RR, Durrani OM, Denniston AK, et al Ocular manifestations of systemic lupus erythematosus. Rheumatology (Oxford) 2007; 46(12):1757-1762
128. Somers E, Magder LS, Petri M. Antiphospholipid antibodies and incidence of venous thrombosis in a cohort of patients with systemic lupus erythematosus. J Rheumatol 2002; 29(12):2531-2536
129. Sontheimer RD, Henderson CL, Grau RH. Drug-induced subacutecutaneous lupus erythematosus: A paradigm for bedside-to-bench patientoriented translational clinical investigation Arch Dermatol Res 2009; 301(1):65-70
130. Spronk P, terBorg E, Kallenberg C. Patients with systemic lupus erythematosus and Jaccoud's arthropathy: A clinical subset with an increased C reactive protein response? Ann Rheum Dis 1992; 51:358-361
131. Stahl NI, Klippel JH, Decker JL. Fever in systemic lupus erythematosus. Am J Med 1979; 67:935-940
132. Suryaprasad A, Stone JH. When is it safe to stop Pneumocystis carinii (jiroveci) prophylaxis? Insights from cases complicating autoimmune diseases. Arthritis Care & Research 2008; 59(7):1034-9
133. Takada K, Illei G, Boumpas D. Cyclophosphamide for the treatment of systemic lupus erythematosus. Lupus 2001; 10:154-161
134. Tam LS, Li EK, Wong CK, Lam CW, Szeto CC. Double-blind, randomized, placebo-controlled pilot study of leflunomide in systemic lupus erythematosus. Lupus 2004; 13(8):601-604
135. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfeld NF, et al The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25:1271-1277
136. Taylor J, Skan J, Erb N, Carruthers D. Lupus patients with fatigue: Is there a link with fi bromyalgia syndrome? Rheumatology 2000; 39: 620-623
137. terBorg E, Horst G, Limburg P, vanRijswijk M, Kallenberg C. C-reactive protein levels during disease exacerbations and infections in systemic lupus erythematosus: A prospective longitudinal study. J Rheumatol 1990 17: 1642-1648
138. Tsakonas E, Joseph L, Esdaile JM, Choquette D, Senecal JL, Cividino A, et al A long-term study of hydroxychloroquine withdrawal on exacerbations in systemic lupus erythematosus. The Canadian Hydroxychloroquine Study Group. Lupus 1998; 7:80-85
139. Tsokos GC. Drugs, sun and T cells in lupus. Clin Exp Immunol 2004; 136(2):191-193
140. Turner-Stokes L, Cambridge G, Corcoran T, et al In vitro response to influenza immunisation by peripheral blood mononuclear cells from patients with systemic lupus erythematosus and other autoimmune disease. Ann Rheum Dis 1988; 47:532-535
141. Tzung TY, Liu YS Chang HW. Tacrolimus vs. clobetasol propionate in the treatment of facial cutaneous lupus erythematosus: A randomized, double-blind, bilateral comparison study. Br J Dermatol 2007; 156(1):191-192
142. Ueki H. Koebner phenomenon in lupus erythematosus with special consideration of clinical findings. Autoimmunity reviews 2005; 4(4): 219-223
143. Urowitz MB, Bookman AAM, Koehler BE, Gordon DA, Smythe HA, Ogryzlo MA. The bimodal mortality pattern of systemic lupus erythematosus. Am J Med 1976; 60:221-225
144. Vassilakopoulos TP, Pangalis GA. Application of a prediction rule to select which patients presenting with lymphadenopathy should undergo a lymph node biopsy. Medicine (Baltimore) 2000; 79(5): 338-347
145. Wahl DG, Guillemin F, de Maistre E, Perret C, Lecompte T, Thibaut G. Risk for venous thrombosis related to antiphospholipid antibodies in systemic lupus erythematosus: A meta-analysis. Lupus 1997;6: 467-473
146. Walz LeBlanc BAE, Gladman DD, Urowitz MB. Serologically active clinically quiescent systemic lupus erythematosus: Predictors of clinical fl ares. J Rheumatol 1994; 21:2239-2241
147. Ward MM, Donald F. Pneumocystis carinii pneumonia in patients with connective tissue diseases: The role of hospital experience in diagnosis and mortality. [Journal Article] Arthritis Rheum 1999 Apr; 42(4):780-789
148. Wassner SJ, Pennisi AJ, Malekzadeh MH, et al The adverse effect of anticonvulsant therapy on renal allograft survival. A preliminary report. J Pediatr 1976; 88:134-137
149. Wells JV, Webb J, Van Deventer M, et al In vivo anti-nuclear antibodies in epithelial biopsies in SLE and other connective tissue diseases. Clin Exp Immunol 1979; 38(3):424-435
150. Werth VP, Sanchez M, White W, et al Incidence of alopecia areata in lupus erythematosus. Arch Derm 1992; 128:368-371
151. Wilson H, Hamilton M, Spyker D, et al Age influences the clinical and serologic expression of systemic lupus erythematosus. Arthritis Rheum 1981; 24:1230-1235
152. Zandman-Goddard G, Shoenfeld Y. SLE and infections. Clin Rev Allergy Immunol 2003; 25:29-40